Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Futura Medical ( (GB:FUM) ) is now available.
Futura Medical announced a board change with Harmesh Suniara stepping down as Non-Executive Director following a significant reduction in Lombard Odier Asset Management’s shareholding. The company, having secured a strong financial position through recent fundraising, is now concentrating on completing a strategic review and advancing its product development efforts, particularly Eroxon Intense and WSD4000, to strengthen its market position.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products. Their primary products include Eroxon®, a topical gel for erectile dysfunction, and development products WSD4000 and Eroxon® Intense. The company focuses on addressing unmet needs in the sexual health market for both men and women, with distribution partnerships in major markets such as the US and Europe.
Average Trading Volume: 2,956,141
Technical Sentiment Signal: Sell
Current Market Cap: £3.7M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.